tradingkey.logo

Moderna Inc

MRNA

27.160USD

-0.380-1.38%
Close 06/27, 16:00ETQuotes delayed by 15 min
10.51BMarket Cap
LossP/E TTM

Moderna Inc

27.160

-0.380-1.38%
More Details of Moderna Inc Company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Company Info
Ticker SymbolMRNA
Company nameModerna Inc
IPO dateDec 07, 2018
Founded at2016
CEOMr. Stephane Bancel
Number of employees5800
Security typeOrdinary Share
Fiscal year-endDec 07
Address325 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone16177146500
Websitehttps://www.modernatx.com/
Ticker SymbolMRNA
IPO dateDec 07, 2018
Founded at2016
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.19K
+3.64%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.19K
+3.64%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
COVID
3.08B
99.20%
RSV
25.00M
0.80%
By RegionUSD
Name
Revenue
Proportion
United States
1.78B
57.41%
Rest of the World
853.00M
27.44%
Europe
598.00M
19.23%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.64%
Investment Advisor/Hedge Fund
25.28%
Hedge Fund
7.51%
Corporation
4.68%
Research Firm
4.38%
Individual Investor
2.56%
Bank and Trust
2.36%
Pension Fund
1.27%
Venture Capital
1.21%
Other
20.11%
Institutional Shareholding
Updated: Mon, Jan 20
Updated: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
2090
308.33M
79.76%
-16.50M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
2022Q4
2442
300.08M
77.99%
-2.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
40.18M
10.39%
+101.25K
+0.25%
Dec 31, 2024
Baillie Gifford & Co.
38.89M
10.06%
-3.57M
-8.40%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.38M
4.75%
+1.28M
+7.51%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
18.04M
4.67%
+471.49K
+2.68%
Dec 31, 2024
State Street Global Advisors (US)
17.58M
4.55%
+730.02K
+4.33%
Dec 31, 2024
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Geode Capital Management, L.L.C.
7.24M
1.87%
+171.77K
+2.43%
Dec 31, 2024
Theleme Partners LLP
7.31M
1.89%
+80.00K
+1.11%
Dec 31, 2024
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Global X Genomics & Biotechnology ETF
3.72%
Langar Global HealthTech ETF
3.53%
First Trust NYSE Arca Biotechnology Index Fund
3.1%
iShares Genomics Immunology and Healthcare ETF
2.86%
VanEck Biotech ETF
2.08%
SPDR S&P Biotech ETF
1.84%
WisdomTree BioRevolution Fund
1.64%
Federated Hermes MDT Large Cap Value ETF
1.43%
Invesco S&P 500 Equal Weight Health Care ETF
1.28%
ROBO Global Healthcare Technology & Innovation ETF
1.27%
View more
Global X Genomics & Biotechnology ETF
Proportion3.72%
Langar Global HealthTech ETF
Proportion3.53%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.1%
iShares Genomics Immunology and Healthcare ETF
Proportion2.86%
VanEck Biotech ETF
Proportion2.08%
SPDR S&P Biotech ETF
Proportion1.84%
WisdomTree BioRevolution Fund
Proportion1.64%
Federated Hermes MDT Large Cap Value ETF
Proportion1.43%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion1.28%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.27%
Dividend
A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI